Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin

Vaccaro, O., Masulli, M., Bonora, E., Del Prato, S., Giorda, C., Maggioni, A., et al. (2012). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 22(11), 997-1006 [10.1016/j.numecd.2012.09.003].

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial

MOCARELLI, PAOLO;BRAMBILLA, PAOLO;TREVISAN, ROBERTO
2012

Abstract

Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin
Articolo in rivista - Articolo scientifico
Questionnaires; Endpoint Determination; Sulfonylurea Compounds; Humans; Metformin; Thiazolidinediones; Quality of Life; Aged; Body Mass Index; Blood Glucose; Drug Therapy, Combination; Hypoglycemic Agents; Risk Factors; Diabetes Mellitus, Type 2; Treatment Outcome; Middle Aged; Cardiovascular Diseases; Follow-Up Studies; Female; Male
English
2012
22
11
997
1006
open
Vaccaro, O., Masulli, M., Bonora, E., Del Prato, S., Giorda, C., Maggioni, A., et al. (2012). Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 22(11), 997-1006 [10.1016/j.numecd.2012.09.003].
File in questo prodotto:
File Dimensione Formato  
Tosca 2012.pdf

accesso aperto

Dimensione 241.31 kB
Formato Adobe PDF
241.31 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/45849
Citazioni
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
Social impact